125 related articles for article (PubMed ID: 8573395)
1. Structural modification of serum vitamin D3-binding protein and immunosuppression in AIDS patients.
Yamamoto N; Naraparaju VR; Srinivasula SM
AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1373-8. PubMed ID: 8573395
[TBL] [Abstract][Full Text] [Related]
2. Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients.
Yamamoto N; Naraparaju VR; Asbell SO
Cancer Res; 1996 Jun; 56(12):2827-31. PubMed ID: 8665521
[TBL] [Abstract][Full Text] [Related]
3. Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus.
Yamamoto N; Naraparaju VR; Moore M; Brent LH
Clin Immunol Immunopathol; 1997 Mar; 82(3):290-8. PubMed ID: 9073553
[TBL] [Abstract][Full Text] [Related]
4. Prognostic utility of serum alpha-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients.
Yamamoto N; Naraparaju VR; Urade M
Cancer Res; 1997 Jan; 57(2):295-9. PubMed ID: 9000571
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF).
Yamamoto N; Suyama H; Yamamoto N; Ushijima N
Int J Cancer; 2008 Jan; 122(2):461-7. PubMed ID: 17935130
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF).
Yamamoto N; Ushijima N; Koga Y
J Med Virol; 2009 Jan; 81(1):16-26. PubMed ID: 19031451
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of vitamin D-binding protein-derived macrophage activating factor on Ehrlich ascites tumor-bearing mice.
Koga Y; Naraparaju VR; Yamamoto N
Proc Soc Exp Biol Med; 1999 Jan; 220(1):20-6. PubMed ID: 9893164
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.
Yamamoto N; Suyama H; Nakazato H; Yamamoto N; Koga Y
Cancer Immunol Immunother; 2008 Jul; 57(7):1007-16. PubMed ID: 18058096
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor.
Yamamoto N; Naraparaju VR
Cancer Res; 1997 Jun; 57(11):2187-92. PubMed ID: 9187119
[TBL] [Abstract][Full Text] [Related]
10. Preparation of Gc protein-derived macrophage activating factor (GcMAF) and its structural characterization and biological activities.
Mohamad SB; Nagasawa H; Uto Y; Hori H
Anticancer Res; 2002; 22(6C):4297-300. PubMed ID: 12553073
[TBL] [Abstract][Full Text] [Related]
11. Effect of the Gc-derived macrophage-activating factor precursor (preGcMAF) on phagocytic activation of mouse peritoneal macrophages.
Uto Y; Yamamoto S; Takeuchi R; Nakagawa Y; Hirota K; Terada H; Onizuka S; Nakata E; Hori H
Anticancer Res; 2011 Jul; 31(7):2489-92. PubMed ID: 21873164
[TBL] [Abstract][Full Text] [Related]
12. Pathogenic significance of alpha-N-acetylgalactosaminidase activity found in the envelope glycoprotein gp160 of human immunodeficiency virus Type 1.
Yamamoto N
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):262-71. PubMed ID: 16545013
[TBL] [Abstract][Full Text] [Related]
13. Tumor cell alpha-N-acetylgalactosaminidase activity and its involvement in GcMAF-related macrophage activation.
Mohamad SB; Nagasawa H; Uto Y; Hori H
Comp Biochem Physiol A Mol Integr Physiol; 2002 May; 132(1):1-8. PubMed ID: 12062184
[TBL] [Abstract][Full Text] [Related]
14. Role of vitamin D3-binding protein in activation of mouse macrophages.
Yamamoto N; Naraparaju VR
J Immunol; 1996 Aug; 157(4):1744-9. PubMed ID: 8759764
[TBL] [Abstract][Full Text] [Related]
15. Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells.
Yamamoto N; Kumashiro R
J Immunol; 1993 Sep; 151(5):2794-802. PubMed ID: 8360493
[TBL] [Abstract][Full Text] [Related]
16. β-Galactosidase treatment is a common first-stage modification of the three major subtypes of Gc protein to GcMAF.
Uto Y; Yamamoto S; Mukai H; Ishiyama N; Takeuchi R; Nakagawa Y; Hirota K; Terada H; Onizuka S; Hori H
Anticancer Res; 2012 Jun; 32(6):2359-64. PubMed ID: 22641675
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF.
Yamamoto N; Suyama H; Yamamoto N
Transl Oncol; 2008 Jul; 1(2):65-72. PubMed ID: 18633461
[TBL] [Abstract][Full Text] [Related]
18. Structural definition of a potent macrophage activating factor derived from vitamin D3-binding protein with adjuvant activity for antibody production.
Yamamoto N
Mol Immunol; 1996 Oct; 33(15):1157-64. PubMed ID: 9070663
[TBL] [Abstract][Full Text] [Related]
19. Phenotype of Gc-globulin influences the macrophage activating factor (MAF) levels in serum.
Debruyne E; Speeckaert M; Weygaerde YV; Delanghe J
Clin Chem Lab Med; 2011 Nov; 49(11):1855-60. PubMed ID: 21859424
[TBL] [Abstract][Full Text] [Related]
20. Association of the macrophage activating factor (MAF) precursor activity with polymorphism in vitamin D-binding protein.
Nagasawa H; Sasaki H; Uto Y; Kubo S; Hori H
Anticancer Res; 2004; 24(5C):3361-6. PubMed ID: 15515432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
